Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials.

Autor: Nguyen VT; Université de Paris, Centre of Research Epidemiology and Statistics (CRESS), Inserm, F-75004 Paris, France; Cochrane France, AP-HP, 75004 Paris, France. Electronic address: van.nguyen@clinicalepidemio.fr., Rivière P; VisionsCarto, France; Ecole Centrale Lyon, LIRIS CNRS, 69134 Écully, France., Ripoll P; INSA Lyon, LIRIS CNRS, 69621 Villeurbanne, France., Barnier J; Centre Max Weber, CNRS, 69007 Lyon, France., Vuillemot R; Ecole Centrale Lyon, LIRIS CNRS, 69134 Écully, France., Ferrand G; Cochrane France, AP-HP, 75004 Paris, France., Cohen-Boulakia S; Laboratoire de Recherche en Informatique (LRI), Université Paris-Saclay, CNRS, 91405 Orsay, France., Ravaud P; Université de Paris, Centre of Research Epidemiology and Statistics (CRESS), Inserm, F-75004 Paris, France; Cochrane France, AP-HP, 75004 Paris, France; Centre d'Epidémiologie Clinique, Hôpital Hôtel Dieu, Assistance Publique des Hôpitaux de Paris (APHP), F-75004 Paris, France., Boutron I; Université de Paris, Centre of Research Epidemiology and Statistics (CRESS), Inserm, F-75004 Paris, France; Cochrane France, AP-HP, 75004 Paris, France; Centre d'Epidémiologie Clinique, Hôpital Hôtel Dieu, Assistance Publique des Hôpitaux de Paris (APHP), F-75004 Paris, France.
Jazyk: angličtina
Zdroj: Journal of clinical epidemiology [J Clin Epidemiol] 2021 Feb; Vol. 130, pp. 107-116. Date of Electronic Publication: 2020 Oct 21.
DOI: 10.1016/j.jclinepi.2020.10.010
Abstrakt: Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated.
Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered.
Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1-Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33-67]; 15-163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients.
Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.
(Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: